About
General Proximity:GENERAL PROXIMITY ANNOUNCES MULTI-TARGET COLLABORATION WITH DAIICHI SANKYO TO DISCOVER AND ADVANCE NOVEL ONCOLOGY THERAPEUTICS USING OMNITAC™ PLATFORM
Daiichi Sankyo Co Ltd :DATROWAY® PLUS RILVEGOSTOMIG SHOWED PROMISING TUMOR RESPONSES IN PATIENTS WITH METASTATIC UROTHELIAL CANCER IN TROPION-PANTUMOR03 PHASE 2 TRIALDAIICHI SANKYO CO LTD - DATROWAY PLUS RILVEGOSTOMIG SHOWS 68.2% RESPONSE RATEDAIICHI SANKYO CO LTD - DATROWAY PLUS RILVEGOSTOMIG SAFETY PROFILE CONSISTENT
Oct 1 (Reuters) - Daiichi Sankyo Co Ltd (4568.T) :* ENHERTU® FOLLOWED BY THP SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION ACCEPTED IN THE U.S. FOR PATIENTS WITH HIGH-RISK HER2 POSITIVE EARLY-STAGE BREAST CANCER PRIOR TO SURGERY* DAIICHI SANKYO CO LTD - FDA TARGET ACTION DATE FOR ENHERTU IS MAY 18, 2026 Source text: Further company coverage: (4568.T)